• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

J Clin Pharmacol 2014 Mar;54(3):279-81

Does an increase in serum creatinine always reflect renal injury? The case of Stribild(R)

Arya V, Florian J, Marcus KA, Reynolds KS, Lewis LL, Sherwat AI

Abstract

Single tablet, once-daily HIV treatment regimens offer patient convenience, the potential for increased adherence, and fewer patient-related dosing errors[1] . Stribild(R) (manufactured and marketed by Gilead Sciences; referred to as "applicant" in this report), a 4-drug fixed-dose combination (FDC) tablet, is approved for the treatment of HIV-1 infection in treatment-naive adult patients. Stribild(R) contains elvitegravir (an integrase strand transfer inhibitor), cobicistat (an inhibitor of cytochrome P450 enzymes), and the nucleoside/nucleotide reverse transcriptase inhibitors emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF).


Category: Journal Article
PubMed ID: #24214102 DOI: 10.1002/jcph.223
Includes FDA Authors from Scientific Area(s): Drugs
Entry Created: 2013-11-12 Entry Last Modified: 2014-04-05
Feedback
-
-